Global News Canada3d ago
Common antidepressant may help adults with long COVID: study
The clinical trial showed a 99 per cent probability that fluvoxamine outperformed placebo for 'reducing fatigue severity and improving quality of life in people with long COVID.'
#Canada #Health #Fluvoxamine #longcovid
https://globalnews.ca/news/11752953/common-antidepressant-may-help-adults-long-covid/
Global News3d ago
Common antidepressant may help adults with long COVID: study
The clinical trial showed a 99 per cent probability that fluvoxamine outperformed placebo for 'reducing fatigue severity and improving quality of life in people with long COVID.'
#Canada #Health #Fluvoxamine #longcovid
https://globalnews.ca/news/11752953/common-antidepressant-may-help-adults-long-covid/
Global News | Breaking, Latest News and Video for Canada3d ago

Common antidepressant may help adults with long COVID: study

https://fed.brid.gy/r/https://globalnews.ca/news/11752953/common-antidepressant-may-help-adults-long-covid/

Global News National3d ago
Common antidepressant may help adults with long COVID: study
The clinical trial showed a 99 per cent probability that fluvoxamine outperformed placebo for 'reducing fatigue severity and improving quality of life in people with long COVID.'
#Canada #Health #Fluvoxamine #longcovid
https://globalnews.ca/news/11752953/common-antidepressant-may-help-adults-long-covid/
Giuseppe MichieliNov 17, 2023
Higher-Dose #Fluvoxamine and Time to Sustained #Recovery in #Outpatients With #COVID19, JAMA: https://jamanetwork.com/journals/jama/fullarticle/2812204?guestAccessKey=54d3e80d-56e9-4898-af7f-16af89f61123&utm_source=silverchair&utm_medium=email&utm_campaign=article_alert-jama&utm_content=olf&utm_term=111723&adv=000003719403
Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19

This randomized study examines the effect of higher-dose fluvoxamine on time to sustained recovery from mild to moderate COVID-19 or progression to severe disease in nonhospitalized adults.

Giuseppe MichieliOct 28, 2023
The real-world #effectiveness of #fluvoxamine #therapy in mild to moderate #COVID19 patients https://pubmed.ncbi.nlm.nih.gov/37890224/?utm_source=Feedly&utm_medium=rss&utm_campaign=None&utm_content=10CQYG4wH40EtHVSNOD9mofMx7F21fnuzqLzNKyqhr7y2YTgCd&fc=None&ff=20231028121434&v=2.17.9.post6+86293ac #research
The real-world effectiveness of fluvoxamine therapy in mild to moderate COVID-19 patients; A historical cohort study (Fluvoxa Trial) - PubMed

Fluvoxamine treatment is failed to demonstrate effectiveness in preventing deterioration in mild to moderate COVID-19 and may lead to a higher incidence of pneumonia, hospitalization, and oxygen supplementation, necessitating careful consideration before prescribing the drug for COVID-19.

PubMed
Show threadVictoria Stuart 🇨🇦 🏳️‍⚧️Jun 16, 2023

Bramante CT et al. (2023) Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
The Lancet Infectious Diseases.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00299-2/fulltext

Post-COVID-19 condition (also known as long COVID) is an emerging chronic illness potentially affecting millions of people. ...

#ivermectin #fluvoxamine #SARSCoV2

Medisch ContactJan 13, 2023
Opnieuw geen bewijs dat #fluvoxamine werkt bij milde tot matige #covid. Ditmaal was de vraag of het middel tot sneller herstel leidt. #wetenschap #coronavirus https://www.medischcontact.nl/nieuws/laatste-nieuws/nieuwsartikel/fluvoxamine-zorgt-niet-voor-sneller-herstel-bij-milde-covid.htm?utm_source=twitter&utm_medium=coosto
Fluvoxamine zorgt niet voor sneller herstel bij milde covid

Twee keer daags 50 mg fluvoxamine leidde niet tot een sneller herstel na milde covid dan een placebo. Dat schrijven Matthew McCarthy e.a. in JAMA.

Giuseppe MichieliJan 13, 2023
McCarthy MW, Naggie S, Boulware DR, et al. Effect of #Fluvoxamine vs Placebo on Time to Sustained #Recovery in #Outpatients With Mild to Moderate #COVID19: A Randomized Clinical Trial. JAMA. Published online January 12, 2023. doi:10.1001/jama.2022.24100
Angela M. Reiersen, MD, MPENov 18, 2022
Intro with hashtags: I am a #psychiatrist & #epidemiologist. My research includes #neurodevelopment, #genetics, #epidemiology, & #longitudinalcourse of #ADHD, #Autism, #ASD, #ticDisorders, #TouretteSyndrome, #WolframSyndome, & #schizophrenia. Along with Dr. Eric Lenze, I ran the #StopCOVID #RCTs, which tested #fluvoxamine vs placebo for treatment of outpatients with early #COVID-19. We are also planning a trial of fluvoxamine for #longCOVID (protocol currently under review by IRB)...